Close
Patheon

News Releases

  • 08 Jun 2017

    Highlights:

    • 2Q 2017 revenue of $483 million
    • Net income from continuing operations of $28 million
      • Net income from continuing operations per diluted share of $0.19
    • 2Q 2017 Adjusted EBITDA of $94 million
    • Adjusted net income from continuing operations of $29 million
      • Adjusted net income from continuing operations per diluted share of $0.20
    DURHAM, N.C.--(BUSINESS WIRE)--Patheon N.V. (NYSE: PTHN), a leading global provider of pharmaceutical development and manufacturing services, today reported financial results for the quarter ended April 30, 2017. Second quarter 2017 revenue was $483 million, compared to $469 million in the prior-year period, and second quarter 2017 adjusted EBITDA was $94 million, compared to $98 million in the prior-year period. Revenue for the first six months of fiscal 2017 was $more...
  • 15 May 2017

    -- Patheon Provides Entry into the Attractive, High-growth CDMO Market

    -- Combination Significantly Strengthens Thermo Fisher's Unique Value Proposition for Pharmaceutical and Biotech Customers by Adding Highly Complementary Services

    -- Creates Substantial Synergies and Positions Combined Company to Further Accelerate Growth

    -- Expected to be Immediately and Significantly Accretive to Adjusted Earnings Per Share (EPS)

    Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per share in cash. The transactionmore...
  • 08 May 2017

    Company Invests $26 million in Sterile PDS Suite

    DURHAM, N.C.--(BUSINESS WIRE)--Patheon N.V (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, announced that it has completed an expansion project at its Greenville, NC manufacturing site. The company invested approximately $26 million to update one of its sterile Pharmaceutical Development Services (PDS) suites and to build a state-of-the-art, fully integrated sterile PDS suitemore...

Media Contact

Mari Mansfield
4815 Emperor Blvd.,
Durham, NC 27703
(919) 226-3137
mari.mansfield@patheon.com

 
 

Media Contact

Mari Mansfield
4815 Emperor Blvd.,
Durham, NC 27703
(919) 226-3137
mari.mansfield@patheon.com